A01  Sleep duration and circadian components of the sleep/wake cycle and their association with body mass index and eating behaviors in children. Bernard Fuemmeler, Virginia Commonwealth University, Richmond, VA, United States.

A02  Estimating the current and future cancer burden attributable to obesity in Canada. Darren Brenner, University of Calgary, Calgary, AB, Canada.

A03  Metformin decreases obesity-associated macrophage infiltration and lymphangiogenesis in the tumor microenvironment in a rodent model of breast cancer. Erin Giles, Texas A&M University, College Station, TX, United States.


A05  Impact of demographic and lifestyle factors on breast adipose tissue inflammation. Kristin Campbell, University of British Columbia, Vancouver, BC, Canada.

A06  Reversing the procancer effects of obesity in a mouse model of colon cancer: Diet versus drug. Laura Bowers, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

A07  Supplemental estrogen reverses obesity-induced periprostatic white adipose tissue inflammation in mice. Priya Bhardwaj, Weill Cornell Medicine, New York, NY, United States.

A08  Metabolically active macrophages: A novel mechanistic link between obesity and TNBC. Payal Tiwari, University of Chicago, Chicago, IL, United States.

A10  RAB7-GTPase: Roles in obesity, inflammation, and tumor cell survival. Imoh Okon, Georgia State University, Atlanta, GA, United States.

A11  Weight loss normalizes obesity-associated claudin-low breast cancer progression: Role of mammary fat pad growth factors and immune cell infiltrates. Liza Makowski, University of Tennessee Health Science Center, Memphis, TN, United States.

A12  Brown adipose tissue lipidomic profile and antitumor properties against breast cancer cells: The role of caspase 1/11. Luis Henrique Correa, University of Brasilia, Brasilia, Brazil.

A13  Obesity and Breast Cancer Metastasis: The Role of Inflammation. Shannon McDonell, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
A14  Retrospective pilot study on the association between body mass index and breast inflammation among Hispanic breast cancer patients. Heather Greenlee, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, United States.


A16  The role of CaSR and calcium signaling in obesity-mediated invasive prostate cancer. Blaine Sherman, Texas State University, San Marcos, TX, United States.

A17  Adipose tissue endothelial cell-derived microvesicles are a potential link between obesity and cancer. Anca Dobrian, Eastern Virginia Medical School, Norfolk, VA, United States.

A18  Genetic variants related to insulin-like growth factor-I and insulin resistance and their interactions with lifestyle factors on breast cancer risk: A two-stage random survival forest analysis. Su Yon Jung, University of California, Los Angeles, CA, United States.

A19  Genetic variants related to insulin-like growth factor-I and insulin metabolism pathways and their interactions with lifestyle factors on colorectal cancer risk: A two-stage random survival forest analysis. Su Yon Jung, University of California, Los Angeles, CA, United States.

A20  The Women in Steady Exercise Research (WISER) Survivor Trial: Comparative effectiveness of exercise, weight loss, or their combination, to reduce metabolic biomarkers of recurrence in breast cancer survivors. Kathleen Sturgeon, Pennsylvania State University, Hershey, PA, United States.

A21  A prospective study of obesity, metabolic health, and cancer mortality among blacks and whites. Tomi Akinyemiju, University of Kentucky, Lexington, KY, United States.

A22  Examining the effect of metformin on the proliferation rate of breast cancer cells. Ethan Loftspring, University of Texas, Austin, TX, United States.

A23  Circumventing insulin feedback increases PI3K inhibitor efficacy. Benjamin Hopkins, Weill Cornell Medicine, New York, NY, United States.

A24  Protein intake is associated with increased oxidative stress during chemotherapy regimens in pediatric leukemia and lymphoma patients. Joya Chandra, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A25  Randomized trial evaluating the role of weight loss in overweight/obese men on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). Jeannette Schenk, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

A27  Overweight and obesity alter the survival rate of breast cancer patients depending on the menopausal and hormone receptor status. Xiaozheng Liu, University of Bergen, Bergen, Norway.

A28  Redox-active metabolites predict clinically-relevant non-alcoholic fatty liver disease in the Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS). Bruce Kristal, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States.
A29  Identifying the genetic contributors to liver fat for future studies of cancer risk: The Multiethnic Cohort Adiposity Phenotype Study. Iona Cheng, University of California, San Francisco, San Francisco, CA, United States.

A30  Development, delivery and impact of the Transdisciplinary Research in Energetics and Cancer (TREC) Training Course. Melinda Irwin, Yale School of Public Health, New Haven, CT, United States.

A31  Differential benefit of taxane-based chemotherapy in breast cancer patients according to baseline body mass index. Christine Desmedt, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Brussels, Belgium.

A32  Stromal antigen 1 and colorectal cancer: Implications for obesity-driven CRC carcinogenesis. Mart Angelo Dela Cruz, Boston University Medical Center, Boston, MA, United States.

A33  Body composition changes after diagnosis and survival of patients with advanced pancreatic cancer. Ana Babic, Dana-Farber Cancer Institute, Boston, MA, United States.

A34  Combined impact of health behaviors on incidence of overweight and obesity among U.S. military veterans. Deborah Bookwalter, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States.